Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

Core Insights - Transgene will present a detailed analysis of the neoantigen-specific T cell response from the Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the upcoming SITC Annual Meeting [1][3] - TG4050 is being developed for solid tumors, specifically targeting HPV-negative head and neck cancers, utilizing Transgene's myvac® technology and NEC's AI capabilities [3][5] - The Phase I trial results showed that all patients receiving TG4050 remained disease-free after a minimum of 2-year follow-up, contrasting with a 19% relapse rate in the observational arm [4] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics [5] - TG4050 is the lead asset of the company, representing the first individualized therapeutic vaccine based on the myvac® platform, demonstrating proof of principle in head and neck cancer treatment [5][6] - The company is also advancing other viral vector-based assets, including BT-001, which is in clinical development [5] Clinical Development - TG4050 is currently being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers [3] - A Phase II extension of the trial is ongoing, with patient enrollment currently in progress [4]